Mary E. Brunkow

Last updated

Mary Brunkow
Born1961 (age 6364)
Education University of Washington (BS)
Princeton University (PhD)
Known for FOXP3
Awards Nobel Prize in Physiology or Medicine (2025)
Scientific career
Fields Immunology
Molecular biology
Institutions Institute for Systems Biology
Celltech R&D
Thesis Expression and function of the H19 gene in transgenic mice  (1991)
Doctoral advisor Shirley M. Tilghman

Mary Elizabeth Brunkow [1] (born 1961) is an American molecular biologist and immunologist. She is known for co-identifying the gene later named FOXP3 as the cause of the scurfy mouse phenotype, a finding that became foundational for modern regulatory T cell biology.

Contents

In 2025, she was jointly awarded the Nobel Prize in Physiology or Medicine with Fred Ramsdell and Shimon Sakaguchi for their work in peripheral immune tolerance.

Early life and education

Brunkow was born in 1961 in Portland, Oregon. [2] [3] She graduated at St. Mary's Academy in Portland in 1979. [3]

Brunkow received a Bachelor of Science with a major in molecular and cellular biology from the University of Washington in 1983 [4] and a Doctor of Philosophy in molecular biology from Princeton University in 1991. [5] Her advisor was Shirley M. Tilghman. [5] Her doctoral dissertation was titled Expression and function of the H19 gene in transgenic mice (1991). [1]

Career

Brunkow worked in industry research in the Seattle area, at Celltech R&D in Bothell, Washington, which is where she and Fred Ramsdell performed their Nobel Prize-winning work on FOXP3, [6] and later she became senior program manager at the Institute for Systems Biology in Seattle. [7]

Research

Nobel Prize in Physiology or Medicine 2025: Pivotal role of FoxP3 Treg cells in peripheral immune tolerance. 25-10-06-Nobel-Prize-FOXP3-Hegasy-v02.jpg
Nobel Prize in Physiology or Medicine 2025: Pivotal role of FoxP3 Treg cells in peripheral immune tolerance.

Brunkow is a co-author of the 2001 Nature Genetics paper that identified the scurfy gene product, initially termed scurfin and later known as FOXP3, linking its disruption to a fatal lymphoproliferative disorder in mice. [8] [9]

Brunkow's most cited work mapped the scurfy defect to FOXP3 and demonstrated that loss of this transcription factor drives uncontrolled T cell activation and lethal lymphoproliferation, positioning FOXP3 at the center of peripheral immune tolerance mediated by regulatory T cells. [8] [10] The genetic identification of FOXP3 provided a molecular basis for understanding how the immune system restrains self-reactivity outside the thymus and catalyzed extensive work on regulatory T cell development and function. [11] [12] Subsequent translational work by many groups led to anti-sclerostin therapy including romosozumab, which received regulatory approval and has been reviewed widely in the clinical literature. [13] [14]

Honors and awards

On October 6, 2025, the Nobel Assembly at the Karolinska Institute in Stockholm, Sweden, announced that Brunkow, Fred Ramsdell, and Shimon Sakaguchi would share the Nobel Prize in Physiology or Medicine for discoveries concerning peripheral immune tolerance. [15] [16]

References

  1. 1 2 Brunkow, Mary Elizabeth. "Expression and function of the H19 gene in transgenic mice". ProQuest. Retrieved October 6, 2025.
  2. "Mary E. Brunkow – Facts". The Nobel Prize. Retrieved October 6, 2025.
  3. 1 2 "Scientist who graduated from Portland high school wins Nobel Prize in medicine". The Oregonian. October 6, 2025. Retrieved October 6, 2025.
  4. "UW alum Mary E. Brunkow awarded the 2025 Nobel Prize in Physiology or Medicine". University of Washington. October 6, 2025. Retrieved October 6, 2025.
  5. 1 2 "Princeton alumna Mary Brunkow *91 receives Nobel Prize in Physiology or Medicine". Princeton University. October 6, 2025.
  6. "Nobel Prize in Physiology or Medicine 2025". NobelPrize.org. Retrieved October 6, 2025.
  7. Fuller-Wright, Liz (October 6, 2025). "Princeton alumna Mary Brunkow *91 receives Nobel Prize in Physiology or Medicine". www.princeton.edu. Retrieved October 7, 2025.
  8. 1 2 Brunkow, Mary E.; Jeffery, Eric W.; Hjerrild, Kathryn A.; Paeper, Bryan; Clark, Lisa B.; Yasayko, Sue-Ann; Wilkinson, J. Erby; Galas, David; Ziegler, Steven F.; Ramsdell, Fred (2001). "Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse". Nature Genetics. 27 (1): 68–73. doi:10.1038/83784. PMID   11138001.
  9. "FOXP3 and scurfy: how it all began" (PDF). Nature Reviews Immunology. 14 (5): 343–349. 2014. doi:10.1038/nri3650. PMID   24722479.
  10. Bluestone, Jeffrey A. (2017). "FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance". The Journal of Immunology. 198 (3): 979–980. doi:10.4049/jimmunol.1602060.
  11. "FOXP3 and scurfy: how it all began" (PDF). Nature Reviews Immunology. 14 (5): 343–349. 2014. doi:10.1038/nri3650. PMID   24722479.
  12. "Development and function of FOXP3+ regulators of immune responses". Clinical and Experimental Immunology. 213 (1): 13–22. 2023. doi:10.1093/cei/uxad048.
  13. Mullard, Asher (May 9, 2019). "FDA approves first-in-class osteoporosis drug". Nature.
  14. "Extending the Therapeutic Potential: Romosozumab in Osteoporosis". Journal of the Endocrine Society. 8 (11) bvae160. 2024.
  15. "The Nobel Prize in medicine goes to 3 scientists for work on peripheral immune tolerance". AP News. October 6, 2025.
  16. "Brunkow, Ramsdell and Sakaguchi win 2025 Nobel medicine prize". Reuters. October 6, 2025.